Ready to elevate your practice's performance?
Ready to elevate your practice's performance? Request your customized demo now!

How your practice can address this condition now and in the future

COVID-19 has forced the world to adapt and change like never before. In a matter of weeks, we’ve seen doctors who have never before offered telemedicine figuring out how to continue caring for their patients. And patients—even elderly, technology-averse ones—are adapting to new ways of connecting with their healthcare providers and educating themselves about their health.Read More

The only lens that can be customized after cataract surgery

Imagine not having to worry about patients’ complaints about refractive errors after cataract surgery. Imagine patients not having to wonder if they made the right decision between monovision or full distance correction. Well, this is now a reality as the “truly disruptive” technology of RxSight Light Adjustable Lens (LAL) will become commercially available in early 2020. It is the first and only lens that can be adjusted after cataract surgery. Read More

A patented in-office procedure plus at-home care gives patients relief from this common condition

Blepharitis is one of the most common eye conditions, and yet it is one of the most under-diagnosed. Why? First, like dry eye or allergies, blepharitis symptoms can be mild or easily mistaken for other issues. So patients may dismiss symptoms, not knowing there’s a name or treatment for what they’re experiencing. Second, blepharitis—by definition, inflammation of the eyelids—often isn’t diagnosed until it is severe, which involves debris or discharge on the lashes.  Read More

Making glaucoma medications easier and more affordable

Eyecare practitioners have several options for the drugs we prescribe to patients. First and generally most expensive, there are the branded, proprietary, patented drugs such as Xiidra, Rocklatan, and Vyzulta. Then there are generics—both branded generics and generics with equivalent active ingredients such as latanoprost, which are much less costly to insurance companies and patients. Read More

A drug for acute NAION is currently in phase III clinical trials

After glaucoma, the second-most common source of optic nerve damage is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). We usually describe this to a patient as a “stroke in the eye,” where blood supply to the optic nerve is cut off due to conditions ranging from hypotension to carotid occlusive disease. This condition typically causes sudden and acute vision loss in one eye, without any pain. Some patients get marginal improvement with time, but usually the prognosis is poor. Read More

It’s safe, more affordable than ever, and useful for numerous indications

If there is one compelling example of the value of ultrasound technology in eye care, it’s an experience I had this past year. I was conducting a retina workshop at the Review of Optometry New Technology and Treatments Conference. To demonstrate how to obtain an ultrasound image, I asked for a volunteer with a pathology or symptom that would warrant a potential B-scan.Read More